Hookipa Pharma Revenue and Competitors
Estimated Revenue & Valuation
- Hookipa Pharma's estimated annual revenue is currently $19.7M per year.
- Hookipa Pharma's estimated revenue per employee is $216,703
- Hookipa Pharma's total funding is $149.3M.
Employee Data
- Hookipa Pharma has 91 Employees.
- Hookipa Pharma grew their employee count by -40% last year.
Hookipa Pharma's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO | Reveal Email/Phone |
2 | CEO | Reveal Email/Phone |
3 | VP Global Head People, Member des Vorstands | Reveal Email/Phone |
4 | Head Information Technology | Reveal Email/Phone |
5 | Head Human Resources | Reveal Email/Phone |
6 | VP Immuno-Oncology, Clinical Research & Development at HOOKIPA Biotech | Reveal Email/Phone |
7 | VP Global Clinical Operations Consultant | Reveal Email/Phone |
8 | VP and Head Quality, Qualified Person | Reveal Email/Phone |
9 | VP, Head Investor Relations and Corporate Communications | Reveal Email/Phone |
10 | VP - Preclinical & Translational Research | Reveal Email/Phone |
Hookipa Pharma Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $19.7M | 91 | -40% | $149.3M | N/A |
#2 | $15.3M | 99 | 8% | N/A | N/A |
#3 | $2.3M | 11 | -8% | N/A | N/A |
#4 | $15.3M | 99 | 8% | N/A | N/A |
#5 | $10.1M | 65 | -8% | N/A | N/A |
#6 | $15.3M | 111 | 31% | N/A | N/A |
#7 | $9.6M | 62 | 2% | N/A | N/A |
#8 | $5.1M | 29 | -6% | N/A | N/A |
What Is Hookipa Pharma?
Hookipa Pharma Inc. is a clinical stage company developing products to prevent and cure infectious diseases and cancer. With this goal in mind we created unique and cutting-edge technologies which reprogram and stimulate the immune system. Our Arenavirus technologies, Vaxwave®, a replication-deficient viral vector, and TheraT®, an attenuated replicating vector, induce potent pathogen-neutralizing antibodies and CD8+ T cells. Both, Vaxwave® and TheraT®, can be administered repeatedly while maintaining their efficacy. TheraT® induced CD8+ T cell responses to tumor antigens reach frequencies and potencies matching or exceeding those observed after adoptive T cell therapy. Hookipa?s ?off-the shelf? viral vectors are administered systemically. They target dendritic cells in vivo and activate the immune system. In immune-oncology, this mechanism enables to fight solid tumors systemically, both primary and secondary (metastatic). At Hookipa we have successfully completed a Phase 1 trial of a Vaxwave®-based prophylactic vaccine to protect against cytomegalovirus (CMV) infections. A proof-of concept trial in solid organ transplant patients will start imminently. We have forged a landmark partnership with Gilead Sciences Inc. to jointly research and develop functional cures for HIV and Hepatitis B infections. We are building a proprietary immune-oncology pipeline by targeting TheraT® towards HPV+ head and neck squamous cell carcinoma and prostate cancer.
keywords:N/A$149.3M
Total Funding
91
Number of Employees
$19.7M
Revenue (est)
-40%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Hookipa Pharma News
HOOK receives a Bearish rating from InvestorsObserver Stock Sentiment Indicator. Sentiment Score - ,bearish. Hookipa Pharma Inc has a Bearish...
NEW YORK and VIENNA, Austria, April 20, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, 'HOOKIPA'), a company developing a new...
HOOKIPA Pharma Inc. shares rose 15% to $2.03 as the company reported positive preclinical data for its cancer-focused immunotherapies.
Comprehensive review highlights potential of HOOKIPA’s versatile arenavirus platform as a new immunotherapy strategy to address critical unmet needs in cancer Pre-clinical and clinical data showcase potent, tumor-specific CD8+ T cell responses following intravenous administration of arenaviral ...
NEW YORK and VIENNA, Austria - HOOKIPA Pharma Inc. (NASDAQ: HOOK, 'HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced it has entered into a clinical collaboration and supply agreement with Merck & Co., Inc., Kenilworth, NJ., ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $25.1M | 91 | 3% | N/A |
#2 | N/A | 91 | 47% | N/A |
#3 | $16.4M | 91 | 25% | N/A |
#4 | $13.5M | 93 | -7% | N/A |
#5 | $15.4M | 93 | -9% | N/A |